Cargando…

Cardio-selective versus non-selective β-blockers for cardiovascular events and mortality in long-term dialysis patients: A systematic review and meta-analysis

BACKGROUND: Trials in patients receiving dialysis have demonstrated that β-blockers reduce all-cause mortality and cardiovascular events. However, differences still exist within-class comparative effectiveness studies of the therapeutic benefits of β-blockers in dialysis patients. OBJECTIVE: The pur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tao, Shaohua, Huang, Junlin, Xiao, Jie, Ke, Guibao, Fu, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762568/ https://www.ncbi.nlm.nih.gov/pubmed/36534654 http://dx.doi.org/10.1371/journal.pone.0279171

Ejemplares similares

Effectiveness comparison of cardio-selective to non-selective β-blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study
por: Shireman, Theresa I., et al.
Publicado: (2016)

Risk of Cardiovascular Events in Patients With Diabetes Mellitus on β-Blockers
por: Tsujimoto, Tetsuro, et al.
Publicado: (2017)

Metformin Use and Risk of All-Cause Mortality and Cardiovascular Events in Patients With Chronic Kidney Disease—A Systematic Review and Meta-Analysis
por: Hu, Yao, et al.
Publicado: (2020)

Association of sclerostin with cardiovascular events and mortality in dialysis patients
por: Zou, Yun, et al.
Publicado: (2020)

Premorbid β1-selective (but not non-selective) β-blocker exposure reduces intensive care unit mortality among septic patients
por: Kuo, Ming-Jen, et al.
Publicado: (2021)

Real-World Effectiveness of Beta-Blockers versus Other Antihypertensives in Reducing All-Cause Mortality and Cardiovascular Events
por: Foch, Caroline, et al.
Publicado: (2022)

Comparison of ivabradine plus β-blockers versus β-blocker therapy only
por: Aalbers, J
Publicado: (2010)

Effects of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on all-cause mortality, cardiovascular death, and cardiovascular events among peritoneal dialysis patients: A protocol for systematic review
por: Nochaiwong, Surapon, et al.
Publicado: (2020)

Cardio-renal and cardio-hepatic interactions predict cardiovascular events in elderly patients with heart failure
por: Okano, Takahiro, et al.
Publicado: (2020)

Prediction model for cardiovascular events or all-cause mortality in incident dialysis patients
por: Inaguma, Daijo, et al.
Publicado: (2019)

Peritoneal Protein Clearance Is Associated With Cardiovascular Events but Not Mortality in Peritoneal Dialysis Patients
por: Niu, Wei, et al.
Publicado: (2022)

Risk of Hospitalization for Cardiovascular Events with β-Blockers in Hypertensive Patients: A Retrospective Cohort Study
por: Basile, Jan, et al.
Publicado: (2018)

LNA blockers for improved amplification selectivity
por: Prout, Jaime, et al.
Publicado: (2023)

Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease
por: AlHabeeb, Waleed, et al.
Publicado: (2021)

Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease
por: Kubota, Yoshiaki, et al.
Publicado: (2015)

Predictive Value of the Cardio‐Ankle Vascular Index for Cardiovascular Events in Patients at Cardiovascular Risk
por: Miyoshi, Toru, et al.
Publicado: (2021)

The Real Role of β-Blockers in Daily Cardiovascular Therapy
por: Dézsi, Csaba András, et al.
Publicado: (2017)

Cardio- and Neurotoxicity of Selected Anti-COVID-19 Drugs
por: Nicholson, Martin W., et al.
Publicado: (2022)

Different Non-selective β-Blocker Therapy and Risk of Chronic Obstructive Pulmonary Disease
por: Wang, Cheng-Yi, et al.
Publicado: (2019)

The Role of Non-Selective β-Blockers in Compensated Cirrhotic Patients without Major Complications
por: Yeh, Wen-Shuo, et al.
Publicado: (2019)

Effects of β(2)-receptor stimulation by indacaterol in chronic heart failure treated with selective or non-selective β-blockers: a randomized trial
por: Contini, Mauro, et al.
Publicado: (2020)

Characteristic interactivity of landiolol, an ultra-short-acting highly selective β(1)-blocker, with biomimetic membranes: Comparisons with β(1)-selective esmolol and non-selective propranolol and alprenolol
por: Tsuchiya, Hironori, et al.
Publicado: (2013)

Effects of iron-based phosphate binders on mortality and cardiovascular events in patients receiving maintenance dialysis
por: Tanaka, Akihito, et al.
Publicado: (2023)

Impact of a cardio‐oncology unit on prevention of cardiovascular events in cancer patients
por: Cuomo, Alessandra, et al.
Publicado: (2022)

Association of Selected Antipsychotic Agents With Major Adverse Cardiovascular Events and Noncardiovascular Mortality in Elderly Persons
por: Sahlberg, Marie, et al.
Publicado: (2015)

Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease: nationwide cohort study
por: Fu, Edouard L, et al.
Publicado: (2021)

Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link?
por: Jager, Kitty J, et al.
Publicado: (2011)

Continued improvement of cardiovascular mortality in Hungary - impact of increased cardio-metabolic prescriptions
por: Balogh, Sandor, et al.
Publicado: (2010)

Influence of Different Types of β-Blockers on Mortality in Patients on Hemodialysis
por: Kang, Seok-Hui, et al.
Publicado: (2023)

Long‐term mortality and cardiovascular events of seven angiotensin receptor blockers in hypertensive patients: Analysis of a national real‐world database: A retrospective cohort study
por: Lee, Wonjae, et al.
Publicado: (2023)

Considerations of prescribers and pharmacists for the use of non‐selective β‐blockers in asthma and COPD patients: An explorative study
por: Kuipers, Esther, et al.
Publicado: (2018)

Angiotensin Receptor Blockers Decrease the Risk of Major Adverse Cardiovascular Events in Patients with End-Stage Renal Disease on Maintenance Dialysis: A Nationwide Matched-Cohort Study
por: Yang, Chung-Wei, et al.
Publicado: (2015)

Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials
por: Liu, Youxia, et al.
Publicado: (2017)

Pre-Dialysis Visits to a Nephrology Department and Major Cardiovascular Events in Patients Undergoing Dialysis
por: Huang, Chih-Yuan, et al.
Publicado: (2016)

D-53 | Impact of Cardiovascular Diseases, Calcium Channel Blockers and Beta-Blockers on Mortality of Patients Hospitalized with COVID-19
por: Alhusain, Rashid, et al.
Publicado: (2022)

β-Blocker Use and Cardiovascular Outcomes in Hemodialysis: A Systematic Review
por: Tella, Abhinav, et al.
Publicado: (2022)

Cardiovascular mortality in peritoneal dialysis: the impact of mineral disorders
por: Truyts, César, et al.
Publicado: (2021)

Dialysis Modality Selection Among Patients Attending Freestanding Dialysis Facilities
por: Kendix, Michael
Publicado: (1997)

Prognostic value of soluble ST2 and soluble LR11 on mortality and cardiovascular events in peritoneal dialysis patients
por: Choi, Yu Bum, et al.
Publicado: (2020)

The Relation of Clinic and Ambulatory BP with the Risk of Cardiovascular Events and All-Cause Mortality among Patients on Peritoneal Dialysis
por: Georgianos, Panagiotis I., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_csvn4pri5tldj9i1laad586bnt